GlassScriptPhysician profile
Effie A Tsomos
NPI 1487041349
$1,385.02
in general payments reported to CMS, 2019-2025
14 companies · $913 in 2025
The $913 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $54.51 · 2021: $129 · 2022: $24.47 · 2023: $223 · 2024: $41.26 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,176.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $276.24 | 2020-2025 | |
| Insulet Corporation | $209.43 | 2025 | Omnipod |
| Corcept Therapeutics | $203.74 | 2025 | Korlym |
| Horizon Therapeutics Plc | $147.48 | 2023 | Tepezza |
| Ascendis Pharma Endocrinology INC | $147.16 | 2025 | Yorvipath |
| Mannkind Corporation | $115.08 | 2020-2022 | |
| Recordati_rare_diseases_inc. | $107.14 | 2025 | Isturisa |
| Xeris Pharmaceuticals, INC. | $46.30 | 2025 | Gvoke Hypopen, Recorlev |
| Abbott Laboratories | $26.97 | 2023 | Freestyle Libre 2 |
| Amryt Pharma Holdings LTD | $24.71 | 2023 | Myalept |
| Chiesi USA, INC. | $24.59 | 2024 | Myalept |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.83 | 2023 | Jardiance |
| Astellas Pharma US INC | $16.67 | 2024 | Veozah |
| Dexcom, INC. | $15.68 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Effie Tsomos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.